|
شركة Emergent Biosolutions Inc. (EBS) تقييم DCF |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Emergent BioSolutions Inc. (EBS) Bundle
استكشف المستقبل المالي لشركة Emergent Biosolutions Inc. (EBS) مع حاسبة DCF سهلة الاستخدام! أدخل توقعاتك على النمو والهوامش والمصروفات لحساب القيمة الجوهرية لشركة Biosolutions Inc. (EBS) وتعزيز استراتيجية الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,555.4 | 1,792.7 | 1,120.9 | 1,049.3 | 1,013.6 | 932.5 | 857.9 | 789.2 | 726.1 | 668.0 |
| Revenue Growth, % | 0 | 15.26 | -37.47 | -6.39 | -3.4 | -8 | -8 | -8 | -8 | -8 |
| EBITDA | 549.0 | 458.2 | -32.9 | -505.3 | 36.9 | 25.0 | 23.0 | 21.2 | 19.5 | 17.9 |
| EBITDA, % | 35.3 | 25.56 | -2.94 | -48.16 | 3.64 | 2.68 | 2.68 | 2.68 | 2.68 | 2.68 |
| Depreciation | 114.4 | 126.3 | 148.9 | 125.1 | 108.8 | 93.9 | 86.4 | 79.5 | 73.1 | 67.3 |
| Depreciation, % | 7.36 | 7.05 | 13.28 | 11.92 | 10.73 | 10.07 | 10.07 | 10.07 | 10.07 | 10.07 |
| EBIT | 434.6 | 331.9 | -181.8 | -630.4 | -71.9 | -68.9 | -63.4 | -58.3 | -53.6 | -49.3 |
| EBIT, % | 27.94 | 18.51 | -16.22 | -60.08 | -7.09 | -7.39 | -7.39 | -7.39 | -7.39 | -7.39 |
| Total Cash | 621.3 | 576.1 | 642.6 | 111.7 | 99.5 | 279.5 | 257.1 | 236.6 | 217.6 | 200.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 230.9 | 278.9 | 159.2 | 191.0 | 154.5 | 145.6 | 133.9 | 123.2 | 113.3 | 104.3 |
| Account Receivables, % | 14.85 | 15.56 | 14.2 | 18.2 | 15.24 | 15.61 | 15.61 | 15.61 | 15.61 | 15.61 |
| Inventories | 307.0 | 350.8 | 351.8 | 328.9 | 311.7 | 247.6 | 227.8 | 209.6 | 192.8 | 177.4 |
| Inventories, % | 19.74 | 19.57 | 31.39 | 31.34 | 30.75 | 26.56 | 26.56 | 26.56 | 26.56 | 26.56 |
| Accounts Payable | 136.1 | 128.9 | 103.5 | 112.2 | 60.9 | 78.1 | 71.8 | 66.1 | 60.8 | 55.9 |
| Accounts Payable, % | 8.75 | 7.19 | 9.23 | 10.69 | 6.01 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 |
| Capital Expenditure | -141.0 | -225.0 | -115.8 | -51.6 | -22.9 | -73.0 | -67.1 | -61.8 | -56.8 | -52.3 |
| Capital Expenditure, % | -9.07 | -12.55 | -10.33 | -4.92 | -2.26 | -7.82 | -7.82 | -7.82 | -7.82 | -7.82 |
| Tax Rate, % | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 | -33.38 |
| EBITAT | 326.4 | 231.7 | -183.5 | -655.7 | -95.9 | -61.3 | -56.4 | -51.9 | -47.7 | -43.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -102.0 | 34.0 | -57.1 | -582.4 | -7.6 | 49.8 | -11.9 | -11.0 | -10.1 | -9.3 |
| WACC, % | 9.66 | 9.24 | 11.63 | 11.63 | 11.63 | 10.76 | 10.76 | 10.76 | 10.76 | 10.76 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 14.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -9 | |||||||||
| Terminal Value | -108 | |||||||||
| Present Terminal Value | -65 | |||||||||
| Enterprise Value | -50 | |||||||||
| Net Debt | 564 | |||||||||
| Equity Value | -614 | |||||||||
| Diluted Shares Outstanding, MM | 53 | |||||||||
| Equity Value Per Share | -11.59 |
What You Will Get
- Real Emergent BioSolutions Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Emergent BioSolutions' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Data: Emergent BioSolutions Inc.’s (EBS) historical financial statements and detailed forecasts.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Analysis: Watch Emergent BioSolutions Inc.’s (EBS) intrinsic value update instantly.
- Intuitive Visuals: Dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-formatted Excel file featuring Emergent BioSolutions Inc. (EBS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and instantly compare different outcomes.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Emergent BioSolutions Inc. (EBS)?
- User-Friendly Interface: Perfectly crafted for both novice users and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your specific analysis needs.
- Real-Time Feedback: Monitor immediate changes to Emergent BioSolutions' valuation as you tweak inputs.
- Preloaded Financial Data: Comes with Emergent BioSolutions' actual financial figures for swift evaluation.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing portfolios in the biotech sector.
- Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Emergent BioSolutions Inc. (EBS) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Emergent BioSolutions Inc. (EBS) are valued in the marketplace.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Emergent BioSolutions Inc. (EBS).
- Real-World Data: Emergent BioSolutions’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Emergent BioSolutions Inc. (EBS).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.